The case for & against
Bull & Bear analysis
Bearish
ALX Oncology (NASDAQ:ALXO) is an emerging biotechnology firm focused on developing therapies for oncology, particularly immuno-oncology treatments. The company's leading product candidate, evorpacept, is designed to enhance the efficacy of existing cancer therapies by targeting specific biomarkers. Positioned within the fast-growing cancer treatment landscape, ALX Oncology aims to leverage its innovative pipeline to address unmet medical needs in treating various malignancies, notably breast cancer.
Bull says
- ↑Phase 1b/2 evorpacept trials show durable responses in HER2-positive patients at ESMO
- ↑$153.4 M cash and equivalents fund operations into mid-2028, extending runway
- ↑High institutional ownership indicates strong investor confidence in pipeline
- ↑Positive momentum and sentiment scores may boost stock ahead of data
- ↑Phase 2 ASPEN-09 topline results expected mid-2027 as key catalyst
Bear says
- ↓Q2 2026 GAAP net loss of $18 M vs $25.9 M prior, full-year loss ~ $1/share
- ↓Negative profitability and growth factors signal ongoing unprofitability
- ↓High leverage raises refinancing and cash-burn concerns
- ↓Negative revisions and growth indicators suggest revenue stagnation
- ↓Disappointing trial data could trigger sell-off and dampen sentiment
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-10-2026bullish
Transcript signals
Bull points
- As we've seen, all of the patients who were centrally assessed as HER2-positive and who overexpressed CD47 in their cancer cells achieved confirmed response to the combination of avorapazep plus anidatinib.
- So these data are really why we're so excited about moving forward with the development of avorpicep in HER2-positive breast cancer.
- We estimate that there are approximately 20,000 addressable patients who are HER2 positive and overexpressed CD47, representing a $2 billion to $4 billion market opportunity in the United States, the five major European markets, and Japan.
Bear points
- I would think that PFS might be too immature to report, but it really depends on the continued progress.
- we do not have an expectation that we could replicate a hundred percent response rate, which are very difficult to achieve, particularly with regulatory approvals for single-arm trials that involve a combination of two agents.
Read full transcript analysis ›